Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein
product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 …
product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 …
Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease
Z Li, B Zhang, Q Liu, Z Tao, L Ding, B Guo, E Zhang… - …, 2023 - thelancet.com
Background Some observational studies found that dyslipidaemia is a risk factor for non-
alcoholic fatty liver disease (NAFLD), and lipid-lowering drugs may lower NAFLD risk …
alcoholic fatty liver disease (NAFLD), and lipid-lowering drugs may lower NAFLD risk …
Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study
W **e, J Li, H Du, J **a - Arthritis research & therapy, 2023 - Springer
Background In addition to decreasing the level of cholesterol, proprotein convertase subtilis
kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the …
kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the …
Breaking the barrier: Nanoparticle-enhanced radiotherapy as the new vanguard in brain tumor treatment
S Liu, MJ Li, B Liang, W Sun, Y Shao, X Hu… - Frontiers in …, 2024 - frontiersin.org
The pursuit of effective treatments for brain tumors has increasingly focused on the
promising area of nanoparticle-enhanced radiotherapy (NERT). This review elucidates the …
promising area of nanoparticle-enhanced radiotherapy (NERT). This review elucidates the …
PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer's disease
B Papotti, MP Adorni, C Marchi, F Zimetti… - International journal of …, 2022 - mdpi.com
The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) involvement in Alzheimer's
disease (AD) is poorly investigated. We evaluated the in vitro PCSK9 modulation of …
disease (AD) is poorly investigated. We evaluated the in vitro PCSK9 modulation of …
Comparing the relationships of genetically proxied PCSK9 inhibition with mood disorders, cognition, and dementia between men and women: a drug‐target …
Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors are important
therapeutic options for reducing cardiovascular disease risk; however, questions remain …
therapeutic options for reducing cardiovascular disease risk; however, questions remain …
[HTML][HTML] Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling
X Han, Y Gao, M He, Y Luo, Y Wei, Y Duan… - Journal of advanced …, 2024 - Elsevier
Introduction Proprotein convertase subtilisin/kexin type 9 (PCSK9) is implicated in the
pathogenesis and progression of autoimmune disease. Patients with rheumatoid arthritis …
pathogenesis and progression of autoimmune disease. Patients with rheumatoid arthritis …
Long-term cognitive safety of achieving very low LDL cholesterol with evolocumab
A Zimerman, ML O'Donoghue, X Ran, KA Im… - NEJM …, 2025 - evidence.nejm.org
Background Concerns persist regarding the cognitive safety of achieving very low levels of
low-density lipoprotein (LDL) cholesterol. Although short-term studies are reassuring, the …
low-density lipoprotein (LDL) cholesterol. Although short-term studies are reassuring, the …
Assessing the impact of PCSK9 and HMGCR inhibition on liver function: drug-target Mendelian randomization analyses in four ancestries
Background & Aims Observational studies have linked lipid-lowering drug targets pro-
protein convertase subtilisin/kexin 9 (PCSK9) and HMG-CoA reductase (HMGCR) with …
protein convertase subtilisin/kexin 9 (PCSK9) and HMG-CoA reductase (HMGCR) with …
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment
Aims PCSK9 inhibition intensively lowers low density lipoprotein cholesterol and is well
tolerated in adults and paediatric patients with familial hypercholesterolaemia (FH) …
tolerated in adults and paediatric patients with familial hypercholesterolaemia (FH) …